Trials / Terminated
TerminatedNCT02385669
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Craig L Slingluff, Jr · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | Checkpoint blockade inhibitor |
| BIOLOGICAL | 6MHP | 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2019-09-18
- Completion
- 2019-09-18
- First posted
- 2015-03-11
- Last updated
- 2020-05-05
- Results posted
- 2019-06-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02385669. Inclusion in this directory is not an endorsement.